207 related articles for article (PubMed ID: 34326839)
1. Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report.
Liu C; Shao J; Dong Y; Xu Q; Zou Z; Chen F; Yan J; Liu J; Li S; Liu B; Shen J
Front Immunol; 2021; 12():685126. PubMed ID: 34326839
[TBL] [Abstract][Full Text] [Related]
2. Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.
Lu F; Ma XJ; Jin WL; Luo Y; Li X
Front Immunol; 2021; 12():690565. PubMed ID: 34054880
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy.
Patel K; Lamm R; Altshuler P; Dang H; Shah AP
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32942580
[TBL] [Abstract][Full Text] [Related]
5. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39
Liu T; Tan J; Wu M; Fan W; Wei J; Zhu B; Guo J; Wang S; Zhou P; Zhang H; Shi L; Li J
Gut; 2021 Oct; 70(10):1965-1977. PubMed ID: 33262196
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Arai K; Yamashita T; Sakai A; Sakai Y; Kagaya T; Yamashita T; Honda M; Kaneko S
Hepatology; 2011 Apr; 53(4):1206-16. PubMed ID: 21480325
[TBL] [Abstract][Full Text] [Related]
8. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
9. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798
[TBL] [Abstract][Full Text] [Related]
10. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
Front Immunol; 2021; 12():765101. PubMed ID: 34675942
[TBL] [Abstract][Full Text] [Related]
12. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion.
Cai Z; Su X; Qiu L; Li Z; Li X; Dong X; Wei F; Zhou Y; Luo L; Chen G; Chen H; Wang Y; Zeng Y; Liu X
Mol Cancer; 2021 Dec; 20(1):164. PubMed ID: 34903219
[TBL] [Abstract][Full Text] [Related]
13. Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges.
Wang L; Wang FS
Hepatol Int; 2019 Sep; 13(5):521-533. PubMed ID: 31352593
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management.
Shirabe K; Motomura T; Muto J; Toshima T; Matono R; Mano Y; Takeishi K; Ijichi H; Harada N; Uchiyama H; Yoshizumi T; Taketomi A; Maehara Y
Int J Clin Oncol; 2010 Dec; 15(6):552-8. PubMed ID: 20963618
[TBL] [Abstract][Full Text] [Related]
15. Potential therapeutic value of dendritic cells loaded with NY‑ESO‑1 protein for the immunotherapy of advanced hepatocellular carcinoma.
Chen Y; Huang A; Gao M; Yan Y; Zhang W
Int J Mol Med; 2013 Dec; 32(6):1366-72. PubMed ID: 24085111
[TBL] [Abstract][Full Text] [Related]
16. Adoptive cell transfer therapy for hepatocellular carcinoma.
Zhang R; Zhang Z; Liu Z; Wei D; Wu X; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):3-11. PubMed ID: 30659408
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic strategies for hepatocellular carcinoma.
Butterfield LH
Gastroenterology; 2004 Nov; 127(5 Suppl 1):S232-41. PubMed ID: 15508089
[TBL] [Abstract][Full Text] [Related]
18. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches.
Kalathil SG; Thanavala Y
Cells; 2021 May; 10(6):. PubMed ID: 34071188
[TBL] [Abstract][Full Text] [Related]
19. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma.
Geissler M; Mohr L; Ali MY; Grimm CF; Ritter M; Blum HE
Z Gastroenterol; 2003 Nov; 41(11):1101-10. PubMed ID: 14648380
[TBL] [Abstract][Full Text] [Related]
20. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]